GLPG Galapagos Genomics Forward P/S Multiple

Corporate company logo of Galapagos N.V. (GLPG)

The stable operation of Galapagos NV production capacities creates a foundation for growth, which is further strengthened by strategic alliances and the acquisition of biotech startups. This chart of the expected P/S metric from the GURU.Markets terminal shows the current level is around 1.40. This price action confirms a trajectory toward leadership in immunology through the implementation of innovative CAR-T therapy, which reduces treatment delivery times for patients.

GLPG glpg.com: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 05/08/2026

Financial and market metric breakdowns for Galapagos NV (GLPG)

- current price and projected stock value:
Stock Price Galapagos N.V.|GLPG - Analyst Target Range
- market capitalization data:
Market Capitalization Galapagos|GLPG - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Galapagos|GLPG - Company Book Value|Market Capitalization to Book Value Ratio glpg.com|GLPG - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Galapagos NV|GLPG - Long-Term Liabilities to Equity|Short-Term Debt to Capital glpg.com|GLPG - Company Aggregate Debts|Debts to Book Capitalization Galapagos NV|GLPG - Long-Term Indebtedness|Company Short-Term Debt Galapagos|Quick Liquidity glpg.com
- business earnings and investment ratios data:
GLPG - Net Financial Result|Future Profit Galapagos NV|GLPG - Company Value to Net Income|Future Price to Earnings Galapagos|GLPG - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Galapagos NV|GLPG - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Galapagos|GLPG - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months glpg.com|GLPG - Earnings per share growth in current year|Net earnings per share growth forecast for next year Galapagos NV
- sales revenue and business income indicators:
GLPG - Company Annual Revenue|Projected Sales Volume Galapagos N.V.|GLPG - Price-to-Revenue Multiple|Price-to-Projected Revenue Ratio Galapagos
Fundamental company analysis:Galapagos N.V. GLPG
Original product of Galapagos Corp

Forward P/S determines the market value of a company relative to expected revenue, calculated as the ratio of current market capitalization to projected sales for a future period. By analyzing the forward P/S ratio, an investor assesses the fairness of the valuation of Galapagos NV (GLPG), where a massive liquidity reserve from partnerships minimizes the risk of cash flow gaps when financing costly R&D projects.

Main competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP